MV-CEA could up-regulate PD-L1 in human GBM cells, and the combination with PD-1 blockade showed an increase in CD8+ TILs and improved OS in mice (134), supporting the potential of clinical combination of MV with αPD-1 therapy in GBM treatment (135). Here, CD8A is linked to glioblastoma.